BioNTech SE (BNTX) Long-Term Debt Issuances (2018 - 2025)
BioNTech SE (BNTX) posted Long-Term Debt Issuances of $215188.0 for Q4 2023, up 97.68% sequentially from $108859.0 in Q3 2023, and up 5.46% YoY from $204049.5 in Q4 2022.
BioNTech SE (BNTX) Long-Term Debt Issuances (2018 - 2025) Analysis & Trends
BioNTech SE has reported Long-Term Debt Issuances for 5 years, with the latest figure at $215188.0 in Q4 2023.
- Quarterly Long-Term Debt Issuances rose 5.46% year-over-year to $215188.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $931406.2 (up 13.47% YoY) and the FY2025 annual result came in at $7.6 million, changed N/A from the prior year.
- Long-Term Debt Issuances advanced to $215188.0 in Q4 2023 per BNTX's latest filing, from $108859.0 in the prior quarter.
- Over five years, Long-Term Debt Issuances peaked at $3.2 million in Q4 2019 and troughed at $63.91 in Q4 2020.
- A 4-year average of $949100.8 and a median of $214299.7 in 2023 frame the typical range for Long-Term Debt Issuances.
- The sharpest annual moves came in 2019 and 2020: Long-Term Debt Issuances surged 214.03% in 2019, then slumped 100.0% in 2020.
- Over 4 years, Long-Term Debt Issuances stood at $3.2 million in 2019, then plunged by 100.0% to $63.91 in 2020, then soared by 319192.59% to $204049.5 in 2022, then grew by 5.46% to $215188.0 in 2023.
- According to Business Quant data, Long-Term Debt Issuances over the past three periods registered $215188.0, $108859.0, and $204049.5 for Q4 2023, Q3 2023, and Q4 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Roivant Sciences | 26.20 Bn | 26.20 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.80 Mn |
| Dec 31, 2025 | 7.80 Mn |
| Dec 31, 2023 | 215,187.98 |
| Dec 31, 2023 | 215,187.98 |
| Sep 30, 2023 | 108,859.05 |
| Sep 30, 2023 | 108,859.05 |
| Dec 31, 2022 | 204,049.47 |
| Dec 31, 2022 | 204,049.47 |
| Sep 30, 2022 | 403,309.73 |
| Sep 30, 2022 | 403,309.73 |
| Jun 30, 2022 | 213,411.34 |
| Jun 30, 2022 | 213,411.34 |
| Dec 31, 2020 | 63.91 |
| Dec 31, 2020 | 63.91 |
| Mar 31, 2020 | 3.20 Mn |
| Mar 31, 2020 | 3.20 Mn |
| Dec 31, 2019 | 3.25 Mn |
| Dec 31, 2019 | 3.25 Mn |
| Dec 31, 2018 | -2.85 Mn |
| Dec 31, 2018 | -2.85 Mn |